EyePoint Pharmaceuticals (EYPT) Tops Q2 EPS by 8c

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q2 EPS of ($0.61), $0.08 better than the analyst estimate of ($0.69). Revenue for the quarter came in at $9.1 million versus the consensus estimate of $79.11 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• JPMorgan Starts Bechtle AG (BC8:GR) (BECTY) at Neutral
• BlackRock’s Rosenberg says inflation data key after jobs beat